Every Form 4 that DENTSPLY SIRONA Inc. (XRAY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XRAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRAY filings page.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky acquired 3,323 phantom stock units on September 30, 2026, at a reported $9.03 per share. Each phantom share is economically equivalent to one common share, and his reported direct phantom-stock balance after the award was 23,345 units. The units become payable in common stock following termination of his service as a director.
DENTSPLY SIRONA Inc. EVP & CFO John C. Fortson reported equity awards. He received 24,014 shares of Common Stock in the form of Restricted Stock Units that vest in one-third annual installments over three years ending August 10, 2029. He was also granted 104,200 stock options to buy Common Stock at an exercise price of $12.83 per share, vesting in similar one-third annual increments through August 10, 2029, and expiring on August 10, 2036.
DENTSPLY SIRONA Inc. executive Andrea L. Frohning, SVP and CHRO, reported a disposition of 802 shares of common stock on 2026-08-07. The shares were withheld to cover taxes related to the vesting of previously reported Restricted Stock Units and dividend equivalent units. After this tax-withholding event, Frohning directly holds 63,190.618 shares of common stock, a figure updated for rounding effects from dividend payments.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a compensation grant of phantom stock units tied to the company’s common stock. On this Form 4, he was awarded 2,841.8303 shares of phantom stock at $10.56 per share, each economically equivalent to one share of common stock. Following this award, his total phantom stock balance is 20,021.6843 units, which will be settled in common stock after his service as a director ends. This is a non-cash, deferred compensation transaction rather than an open-market stock purchase or sale.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky filed an amended insider report clarifying that a recent transaction was an open-market stock purchase. On this amended Form 4, he is shown buying 10,000 shares of common stock at $10.14 per share. Following this transaction, his direct ownership stands at 61,668.534 shares of DENTSPLY SIRONA common stock. The amendment corrects the original coding of the trade, which had been mistakenly reported as an award rather than a market purchase, while leaving all other details unchanged.
DENTSPLY SIRONA Inc. director Clyde Hosein made an open-market purchase of 6,500 shares of common stock at $9.985 per share. Following this transaction, his direct ownership increased to 70,575.456 shares, indicating a higher personal equity stake in the company.
DENTSPLY SIRONA Inc. director Brian P. McKeon reported an open-market purchase of the company’s common stock. On June 12, 2026, a trust associated with him bought 10,000 shares at $10.12 per share, held as indirect ownership. A separate entry shows he directly holds 28,887 common shares following the reported transactions.
DENTSPLY SIRONA Inc. director Brian T. Gladden reported an open-market purchase of 9,985.022 shares of common stock on June 15, 2026. The weighted average purchase price was $10.015 per share, based on multiple trades between $10.015 and $10.0156. Following this transaction, he directly owns 61,848.544 shares of the company’s common stock.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of 10,000 shares of Common Stock on June 12, 2026 at a reported value of $10.14 per share. This compensation-related award increased his directly held stake to 61,668.534 shares, rather than reflecting an open-market purchase.
DENTSPLY SIRONA Inc. director Betsy D. Holden purchased additional shares of the company’s Common Stock in the open market. She bought 10,086 shares on June 11, 2026 at a weighted average price of $9.8842 per share. After this transaction, she directly owns 87,528 shares of DENTSPLY SIRONA Common Stock. The filing notes that the purchase price reflects multiple trades executed between $9.865 and $9.90 per share.
DENTSPLY SIRONA Inc. director Michael J. Barber reported an open-market purchase of Common Stock. On June 11, 2026, he bought 15,175 shares at a weighted average price of $9.885 per share, with individual trades ranging from $9.87 to $9.93. Following this transaction, he directly owns 55,943 shares of the company’s stock.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported a mix of equity awards and family wealth transfers in company stock. He made bona fide gifts of 38,382 shares of Common Stock and 10,900 stock options to a family partnership associated with a trust benefiting him, with his spouse as general partner.
At the same time, he received matching direct awards: 38,382 Restricted Stock Units that vest in full one year from the grant date and 10,900 Non‑Qualified Stock Options with a $9.64 exercise price that vest in one year and expire in 2036. After these transactions, indirect Common Stock holdings reported include 65,000 shares held by a trust and 21,000 shares held in an IRA, while the family partnership is shown with 63,283.284 shares. These moves reflect compensation grants and estate or family planning activity rather than open‑market buying or selling.
DENTSPLY SIRONA Inc. director Donald Zurbay reported a compensation-related equity grant. He acquired 22,822 shares of common stock through a grant coded as an award, with no cash price per share. These are in the form of Restricted Stock Units that vest in full one year from the grant date. After this grant, his directly held common stock position reported in the filing is 29,693 shares.
Vergis Janet S. reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Janet S. Vergis received a grant of 22,822 shares of Common Stock in the form of Restricted Stock Units. The RSUs vest in full one year from the grant date of June 3, 2026. After this award, she directly holds 67,324 shares, reflecting a compensation-related equity grant rather than an open-market purchase or sale.
VARON LESLIE F reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Leslie F. Varon received an equity grant of 22,822 shares in the form of Restricted Stock Units (RSUs). The RSUs vest in full one year from the grant date, meaning the restrictions lapse at that time.
After this award, Varon directly holds 80,364 shares of the company’s common stock, reflecting a routine, compensation-related increase in her ownership rather than an open-market purchase.
MCKEON BRIAN P reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Brian P. McKeon reported an equity compensation award on Form 4. He received 28,887 shares of Common Stock in the form of Restricted Stock Units that were granted at no cash cost and will vest in full one year from the grant date. Following this award, he directly holds 28,887 shares reported in this filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported receiving an equity award of 22,822 shares of Common Stock in the form of Restricted Stock Units. The grant was recorded at no cash price per share and is classified as a grant or award acquisition rather than an open-market purchase or sale.
The RSUs vest in full one year from the grant date, meaning the restrictions lapse after that period. Following this award, Mazelsky’s directly held Common Stock position reported in this filing increased to 51,668.534 shares, showing his updated ownership stake as reflected in this Form 4.
HOSEIN CLYDE reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Clyde Hosein received an equity award of 22,822 shares on June 3, 2026 at no cash cost per share. A footnote explains this grant consists entirely of restricted stock units that vest in full one year from the grant date.
After this compensation-related award, Hosein holds a total of 64,075.456 common shares directly. Because this is a stock grant rather than an open-market purchase, it reflects routine director compensation rather than a discretionary share purchase.
HOLDEN BETSY D reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Betsy D. Holden received an equity grant of 22,822 shares of Common Stock in the form of Restricted Stock Units. The RSUs vest in full one year from the grant date, meaning restrictions lapse at that time. Following this award, she holds a total of 77,441.799 shares directly.
Gladden Brian T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Brian T. Gladden received an equity grant tied to the company’s common stock. The award covers 22,822 shares at a price of $0.00 per share as a compensation grant rather than a market purchase.
The footnotes state this grant consists entirely of Restricted Stock Units (RSUs) that vest in full one year from the grant date, meaning all restrictions lapse at that time if vesting conditions are met. Following this grant, Gladden’s direct holdings increase to 51,863.522 shares of common stock.
DENTSPLY SIRONA Inc. director James D. Forbes reported an acquisition of 28,887 shares of common stock through an equity grant. The grant was made at no cash cost per share and reflects a compensation-related award rather than an open-market purchase.
The award consists entirely of Restricted Stock Units that vest in full one year from the grant date, meaning restrictions lapse at that time if conditions are met. Following this grant, Forbes directly holds a total of 38,887 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Michael J. Barber reported a compensation-related equity grant on Common Stock. He acquired 22,822 shares at a stated price of $0.00 per share, bringing his direct holdings to 40,768 shares after the transaction.
According to the footnote, this grant consists entirely of Restricted Stock Units that vest in full one year from the grant date, meaning the restrictions lapse at that time if service conditions are met.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported a routine tax-related share disposition. On May 22, 2026, 4,095 shares of common stock were withheld at $10.21 per share to cover taxes tied to vesting of his Restricted Stock Units and related dividend equivalent units.
After this withholding, Scavilla directly holds 157,754 shares of DENTSPLY SIRONA common stock. The transaction reflects tax withholding, not an open-market sale or discretionary trade.
MAZELSKY JONATHAN JAY reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky received a grant of phantom stock under the Directors' Deferred Compensation program. The award covers 2,644.6402 phantom stock units at an economic reference price of $11.34 per unit, each tied to one share of common stock.
Following this compensation grant, his balance in this phantom stock account increased to 17,179.8540 units. According to the terms, these phantom stock units are economically equivalent to common shares and will be settled in common stock after his termination of service as a director.
Scavilla Daniel T reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that President and CEO Daniel T. Scavilla received a grant of 3,554.869 shares of phantom stock under a Supplemental Executive Retirement Plan. The phantom stock has an economic value equivalent to common stock at a reference price of $11.43 per share.
The award represents a SERP contribution for the year 2025 based on the 12/31/25 closing price and is held as a derivative interest. These phantom shares will be settled in common stock upon the executive’s termination of employment, and there were 3,554.869 phantom stock units reported as held directly after this grant.
Denti Aldo Mariano Roberto reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, received an award of 829.396 shares of phantom stock under the company’s Supplemental Executive Retirement Plan for 2025, based on the 12/31/25 closing price. Each phantom share is economically equivalent to one share of common stock and becomes payable in common stock when his employment terminates. After this grant, his reported phantom stock balance is 829.396 shares.
Czerney Kevin reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that VP and Chief Accounting Officer Kevin Czerney received a grant of 2,853.551 shares of phantom stock under the company’s Supplemental Executive Retirement Plan. Each phantom share is economically equivalent to one common share and becomes payable in common stock when his employment ends.
Following this award, Czerney holds a total of 6,346.9846 phantom stock shares directly, all tied to the company’s common stock and described as a SERP contribution for 2025 based on the 12/31/25 closing price.
DENTSPLY SIRONA Inc. director-related entity buys shares. A trust associated with director Gregory T. Lucier purchased 15,000 shares of common stock in an open-market transaction at a weighted average price of $12.445 per share. Following this purchase, the trust held 65,000 shares indirectly for his benefit.
Separate indirect holdings reported, with no new transactions shown, include 24,901.284 shares held by a family partnership and 21,000 shares held by a Gregory Lucier IRA.
DENTSPLY SIRONA Inc. director James D. Forbes reported an open-market purchase of common stock. On March 9, 2026, he bought 5,000 shares at $12.48 per share. After this transaction, his directly owned position increased to 10,000 common shares of the company.
DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026. He received stock options for 10,400 shares and a grant of 13,690 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third installments over three years, ending March 4, 2029. The stock options also vest in one-third annual increments through March 4, 2029 and carry an exercise price equal to 110% of the closing share price on the grant date.
Frohning Andrea L. reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. reported that SVP and CHRO Andrea L. Frohning received equity awards on March 4, 2026. She was granted stock options for 121,600 shares and an award of 26,786 restricted stock units, both vesting in equal one-third installments annually through March 4, 2029.
DENTSPLY SIRONA Inc. executive Aldo Mariano Roberto Denti, EVP and Chief Commercial Officer, reported receiving new equity awards. On March 4, 2026, he was granted stock options for 270,200 shares and 59,524 shares of common stock through restricted stock units. Both the RSUs and options vest in one-third annual installments over three years, ending March 4, 2029. The options have an exercise price set at 110% of the company’s closing common stock price on the grant date, aligning the award’s value with future share performance.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported equity compensation awards. He received stock options covering 2,066,600 shares, which vest in annual one-third increments over three years ending March 4, 2029, with an exercise price equal to 115% of the closing price on the grant date.
He also received 145,089 shares of common stock in the form of Restricted Stock Units, vesting one-third annually over the same three-year period ending March 4, 2029. Following these awards, his directly owned common stock holdings increased to 161,839.066 shares, and he directly holds 2,066,600 stock options.
DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported equity awards that increase his direct ownership stake. On March 4, 2026, he was granted stock options for 202,700 rights to buy shares and an award of 44,643 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third annual installments over three years, ending March 4, 2029
DENTSPLY SIRONA Inc. granted stock options to senior executive Robert Anthony Johnson, who serves as SVP and Chief Supply Chain Officer. The award covers 471,400 stock options, recorded as a direct beneficial holding after the transaction.
According to the terms, these options will cliff-vest on the third anniversary of the grant date, meaning none are exercisable until that date. The exercise price will be set at 110% of the closing price of DENTSPLY SIRONA common stock on the grant date, aligning the award’s value with future share performance.
DENTSPLY SIRONA Inc. senior vice president and Chief Supply Chain Officer Robert Anthony Johnson reported share dispositions that were made to cover tax obligations, not open-market sales. On March 4, 2026, 1,026 common shares were withheld at $13.44 per share, leaving 117,176.146 shares held directly.
On March 3, 2026, two similar tax-withholding transactions occurred, with 3,229 and 4,481 common shares withheld at $13.30 per share. Footnotes explain these shares were retained by the company to satisfy taxes due upon vesting of previously granted restricted and performance-based stock units.
DENTSPLY SIRONA Inc. senior vice president and chief human resources officer Andrea L. Frohning reported tax-related share dispositions tied to vesting equity awards. On March 3 and 4, 2026, a total of 5,657 shares of common stock were withheld to cover tax liabilities at prices between $13.30 and $13.44 per share. These are coded as tax-withholding dispositions, not open-market sales. After the most recent withholding, Frohning directly holds 37,206.252 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. reported that officer Kevin Czerney, its VP and Chief Accounting Officer, had company shares withheld to cover tax obligations from vesting equity awards. On March 3, 2026, tax-withholding dispositions of 527 and 1,197 shares of common stock occurred at prices of $13.30 per share. On March 4, 2026, an additional 328 shares were withheld at $13.44 per share. These transactions relate to the vesting of performance-based and time-based restricted stock units and associated dividend equivalent units and are not open-market sales.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported indirect open-market purchases of the company’s common stock through a trust. On March 2 and 3, the trust bought a total of 50,000 shares at weighted average prices of $14.245 and $14.028 per share.
The trust now holds 50,000 shares, while additional indirect holdings shown include 24,901.284 shares through a family partnership and 21,000 shares in a Gregory Lucier IRA. The filing notes the trust is one where Lucier serves as trustee and beneficiary and that he disclaims beneficial ownership beyond his pecuniary interest.
Johnson Robert Anthony reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. senior vice president Robert Anthony Johnson reported an award of 9,599 shares of common stock at no cost, increasing his directly held stake to 125,912.146 shares. The filing also notes that performance criteria for 1,478 performance-based restricted stock units granted on March 3, 2023 were certified as attained on March 2, 2026, with those units scheduled to vest into common shares on March 3, 2026.
DENTSPLY SIRONA Inc. reported that executive Andrea L. Frohning, SVP and CHRO, acquired 8,861 shares of common stock as a stock award. The shares were received at no cash cost per share, increasing her directly held position to 42,863.252 shares.
According to a footnote, this relates to performance-based restricted stock units granted on March 3, 2023. The issuer’s Compensation Committee certified that the performance criteria were met and 1,478 PRSUs were attained on March 2, 2026, with those PRSUs scheduled to vest into shares on March 3, 2026.
DENTSPLY SIRONA Inc. executive Kevin Czerney, the Vice President and Chief Accounting Officer, reported acquiring 1,478 shares of common stock as a grant or award at a price of $0.00 per share. After this award, his directly owned holdings increased to 29,630.908 shares of the company’s common stock.
The award relates to performance-based restricted stock units granted on March 3, 2023, which were certified as attained on March 2, 2026 after the company met specified performance criteria. According to the award terms, these PRSUs vest and convert into shares of common stock on March 3, 2026.
DENTSPLY SIRONA Inc. director James D. Forbes bought 5,000 shares of common stock in an open-market purchase. The shares were acquired at a price of $13.469 per share on 2026-03-03, giving him direct ownership of 5,000 shares following the transaction.
DENTSPLY SIRONA Inc. President and CEO Daniel T. Scavilla reported a small share disposition tied to equity compensation. On the transaction date, 1,194.48 shares of common stock were withheld at a price of $13.14 per share to cover taxes on vested restricted stock units and related dividend equivalent units. After this tax-withholding disposition, Scavilla directly owned 16,750.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Donald Zurbay reported a stock-based award from the company. On 01/26/2026, he was granted 6,871 shares of common stock at a price of $0, reflecting an equity grant rather than a purchase.
According to the footnote, the award consists entirely of Restricted Stock Units that vest in full one year from the grant date, after which the restrictions lapse. Following this grant, Zurbay beneficially owns 6,871 shares directly, aligning his interests more closely with shareholders through additional equity compensation.
DENTSPLY SIRONA Inc. director Janet S. Vergis reported an automatic increase in her equity holdings through dividend equivalents on restricted stock units (RSUs). On January 9, 2026, she was credited with 200.899 shares of common stock at a price of $0, recorded as an acquisition under code A.
These shares represent dividends on existing RSUs, paid in the form of additional RSUs that follow the same vesting schedule as the underlying awards. Each RSU converts into one share of common stock. Following this transaction, Vergis directly beneficially owns 44,501.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Leslie F. Varon reported an acquisition of company equity tied to existing restricted stock units (RSUs). On 01/09/2026, Varon received 198.141 shares of common stock at a price of $0, reflecting dividends on previously granted RSUs that were paid in the form of additional RSUs. These dividend-equivalent RSUs carry the same vesting terms as the underlying awards and will vest at the same time. After this transaction, Varon directly beneficially owned 57,541.066 shares of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. executive Daniel T. Scavilla, the company’s President, CEO and a director, reported acquiring additional common stock through equity compensation. On January 9, 2026, he received 245.816 shares of common stock at $0 per share, recorded as an acquisition. After this transaction, he directly beneficially owned 17,944.546 common shares.
According to the footnote, these shares represent dividends on restricted stock units (RSUs) paid in the form of additional RSUs, which follow the same vesting schedule as the underlying awards. The dividend RSUs vest at the same time as the related RSUs, and each RSU will convert into one share of DENTSPLY SIRONA common stock.
DENTSPLY SIRONA Inc. director Jonathan Jay Mazelsky reported routine equity awards tied to his board service. On January 9, 2026, he acquired 395.158 shares of common stock at $0, representing dividends paid on his existing restricted stock units (RSUs). These dividend RSUs follow the same vesting schedule as the underlying RSUs and each RSU converts into one share of common stock. After this transaction, he beneficially owned 28,846.534 common shares directly.
On the same date, he also acquired 153.7009 phantom stock units under the directors' deferred compensation program at an assigned value of $12.22 per unit, increasing his directly held phantom stock balance to 14,535.2138 units. Each phantom stock unit is economically equivalent to one share of common stock and becomes payable in common stock when his service as a director ends.
DENTSPLY SIRONA Inc. director Gregory T. Lucier reported an automatic award of additional common stock tied to existing restricted stock units. On 01/09/2026, an entity described as a family partnership associated with him received 341.114 shares of common stock at a price of $0, reflecting dividends on his restricted stock units that were paid in the form of additional RSUs.
After this transaction, the family partnership held 24,901.284 common shares indirectly. Separately, an IRA associated with Gregory Lucier held 21,000 common shares indirectly, while his direct common stock holdings were reported as zero. The footnote explains that these dividend RSUs follow the same vesting schedule as the underlying RSU awards and each RSU converts into one share of common stock.